Prothrombin Complex Concentrate Market Estimated to Reach $1.83 Billion, Growing at 7.3% CAGR by 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Is the Prothrombin Complex Concentrate Market Size Expected to Evolve From 2025 to 2029?
The prothrombin complex concentrate market size has grown strongly in recent years. It will grow from $1.29 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rise in the prevalence of bleeding disorders, increased use in warfarin reversal, growth in awareness of coagulation therapies, expansion of surgical procedures, and increased trauma cases.
The prothrombin complex concentrate market size is expected to see strong growth in the next few years. It will grow to " $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing demand for rapid coagulation therapies, increasing prevalence of hemophilia and liver diseases, rising adoption in emergency medicine, expanding applications in cardiac surgeries, and increasing healthcare expenditure. Major trends in the forecast period include integration of AI-driven diagnostics, advancements in recombinant coagulation factors, next-generation recombinant pccs, customized dosing algorithms and advancements in blood plasma products.
Get your free report sample today:
Which Primary Drivers Are Expected to Shape the Future of the Prothrombin Complex Concentrate Market?
The increasing prevalence of bleeding disorders is expected to propel the growth of the prothrombin complex concentrate market going forward. Bleeding disorders are medical conditions where the blood does not clot properly, leading to excessive bleeding due to missing or malfunctioning clotting factors or platelets. Bleeding disorders are increasing mainly due to the rising prevalence of genetic conditions such as hemophilia, increasing cases of liver disease, the growing use of anticoagulant medications, and a higher incidence of vitamin K deficiencies. Prothrombin complex concentrate helps treat bleeding disorders by rapidly replenishing clotting factors, which are essential for effective blood coagulation and hemostasis. For instance, in November 2023, the National Library of Medicine, a U.S.-based medical library, reported that in 2022, a study involving 10,276 individuals with hemophilia was conducted across 87 treatment centers in 40 countries. Nearly 49% of the participants had severe hemophilia, 99% were male, and 85% were diagnosed with hemophilia A. Moreover, 67% of the patients were from low- and middle-income countries. Therefore, the increasing prevalence of bleeding disorders is driving the growth of the prothrombin complex concentrate market.
How Is the Prothrombin Complex Concentrate Market Categorized Based on Key Segments?
The prothrombin complex concentratemarket covered in this report is segmented –
1) By Product: 3-Factor Prothrombin Complex Concentrates; 4-Factor Prothrombin Complex Concentrates; Other Products
2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B); Trauma; Life-Threatening Coagulopathy With Acute Bleeding; Warfarin-Associated Acute, Life-Threatening Bleeding; Non-Warfarin Anticoagulant Reversal With Acute Bleeding
3) By Route Of Administration: Intravenous; Subcutaneous; Intramuscular
4) By End-Use: Hospital And Ambulatory Surgical Centers; Specialty Clinics; Other End Users
Subsegments:
1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC); High-Dose 3-Factor Prothrombin Complex Concentrates (PCC); Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)
2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC); High-Dose 4-Factor Prothrombin Complex Concentrates (PCC); Activated 4-Factor Prothrombin Complex Concentrates (PCC)
3) By Type: Recombinant Coagulation Factor Complexes; Plasma-Derived Coagulation Factor Complexes; Combination Therapy Products
What New Market Trends Are Emerging in the Prothrombin Complex Concentrate Market?
Major companies operating in the prothrombin complex concentrate market are developing innovative formulations such as lyophilized powder to enhance stability, improve storage, and simplify administration. The lyophilized powder is a freeze-dried formulation that removes water to increase shelf life and maintain potency. This allows for better storage conditions and rapid reconstitution for emergency use. For instance, in July 2023, Octapharma USA Inc., a US-based biotechnology company, received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for urgent warfarin reversal in surgeries and invasive procedures. The approval was based on the LEX-209 trial, which showed 94.6% hemostatic efficacy, proving it as effective as Kcentra. This advancement underscores the industry's focus on improving coagulation therapies to enhance patient outcomes in critical care settings.
Who Are the Established and Emerging Companies Competing in the Prothrombin Complex Concentrate Market?
Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., China Biologic Products Holdings Inc.
Get the detailed prothrombin complex concentrate market report today
Which Region Is Expected to Dominate the Prothrombin Complex Concentrate Market During the Forecast Period?
North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment